[1] Wolf- Maier K, CooperRS, BanegasJR, et al. Hyperten? sion prevalnce and blood pressure levels in 6 European coun? tries, Canada, and the United States [J]. JAMA, 2003,289 (18):2363-2369. [/br][2] 张维忠.新型钙拮抗剂贝尼地平基础与临床研究进展[J].中 国高血压,2005,13(4):197-199. [/br][3] 中国高血压防治指南修订委员会.中国高血压防治指南[J].中 国高血压,2011,10(8):701-742. [/br][4] Ohishi M, Takagi T, Ito N. Renal- protective effect of T- and L- type calcium channel blockers in hypertensive patients: an Amlodipine- to- Benidipine Changeover (ABC) study [J]. Hypertens Res, 2007,30(9):797-806. [/br][5] Abe M, Okada K, Maruyama T. Comparison of the antipro? teinuric effects of the calcium channel blockers benidipineand amlodipine administered in combination with angiotensin recep? tor blockers to hypertensive patients with stage 3- 5 chronic kidney disease [J].Hypertens Res, 2009,32(4):270-275. [/br][6] Minatoguchi S. Vasospastic Angina and Ca Channel Blockers [J].Curr Hypertens Rev, 2014, 9(3):219-223. [/br][7] Bramlage P, Hasford J. Bramlagre Blood pressure reduction, persistence and costs in the evaluation of antihypertensive drug treatment a review [J].Cardiovasc Diabetol, 2009(8):18-31. [/br][8] Coll- de- Tuero G, Saez M, Roca- Saumell C. Evolution of target organ damage by different values of self- blood pressure measurement in untreated hypertensive patients [J]. Am J Hypertens, 2012,25(12):1256-1263. [/br][9] Figueiredo VN1, Martins LC, Boer- Martins L. The white coat effect is not associated with additional increase of target or? gan damage in true resistant hypertension [J].Med Clin (Barc), 2013,140(1):1-5. [/br][10] Abe M, Okada K, Suzuki H. T/L-type calcium channel block? er reduces the composite ranking of relative risk according to new KDIGO guidelines in patients with chronic kidney disease [J].BMC Nephrol, 2013,14(1):135. [/br][11] 何月芹,贾连旺,孟仲蔚,等.贝尼地平对老年高血压患者的血压 及心功能的影响[J]. 现代中西医结合杂志,2007,16(23): 3292-3294.